Bibliographie (2546)
The NIH COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19
vendredi, 09 avril 2021 05:47 Écrit par Zouhair SouissiThe COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19 – NIH COVID-19 Treatment Guidelines
The post The NIH COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19 appeared first on Links Medicus.
Commentary | Distinguishing the real from the hyperglycemia: does COVID-19 induce diabetes?
vendredi, 09 avril 2021 05:47 Écrit par Zouhair SouissiDistinguishing the real from the hyperglycaemia: does COVID-19 induce diabetes? – The Lancet Diabetes & Endocrinology
The post Commentary | Distinguishing the real from the hyperglycemia: does COVID-19 induce diabetes? appeared first on Links Medicus.
![[Preprint] CoronaVac is 50% effective for reducing symptomatic SARS-CoV-2 infection after the first dose in the setting of high P.1 variant transmission in Brazil](/media/k2/items/cache/08ae461f14a3d195f7e52b850155dc3c_M.jpg)
[Preprint] CoronaVac is 50% effective for reducing symptomatic SARS-CoV-2 infection after the first dose in the setting of high P.1 variant transmission in Brazil
vendredi, 09 avril 2021 05:47 Écrit par Zouhair SouissiEffectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study – medRxiv Commentary on Twitter (thread – click for more) New 50% efficacy study of Brazil-predominant vaccine CoronaVac (by Sinovac) in Manaus ?? among healthcare workers when #P1 ~75% dominant. Not a trial, but the study […]
The post [Preprint] CoronaVac is 50% effective for reducing symptomatic SARS-CoV-2 infection after the first dose in the setting of high P.1 variant transmission in Brazil appeared first on Links Medicus.
Study: Outdoor transmission accounts for 0.1% of Covid-19 cases
jeudi, 08 avril 2021 15:05 Écrit par Zouhair SouissiOutdoor transmission accounts for 0.1% of State’s Covid-19 cases – The Irish Times Related: Systematic review: Outdoor transmission of SARS-CoV-2 and other respiratory viruses. “The odds of indoor transmission was very high compared to outdoors (18.7 times)”
The post Study: Outdoor transmission accounts for 0.1% of Covid-19 cases appeared first on Links Medicus.
WHO Interim statement: A causal relationship between the AstraZeneca COVID-19 vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed
jeudi, 08 avril 2021 15:05 Écrit par Zouhair SouissiInterim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine – World Health Organization Commentary on Twitter (thread – click for more) ? Interim statement of the #COVID19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on the AstraZeneca vaccine https://t.co/p8XMMAiUne pic.twitter.com/7DMRNFxQsX — […]
The post WHO Interim statement: A causal relationship between the AstraZeneca COVID-19 vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed appeared first on Links Medicus.
Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions
jeudi, 08 avril 2021 15:04 Écrit par Zouhair Souissi6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records – The Lancet Psychiatry Commentaries: 1 in 3 Covid-19 patients are diagnosed with a neuropsychiatric condition in the next six months, large study finds – STAT AND A longer look at COVID-19 and neuropsychiatric outcomes – The […]
The post Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions appeared first on Links Medicus.
Cohort study: One in ten have long-term effects 8 months following mild COVID-19
jeudi, 08 avril 2021 15:04 Écrit par Zouhair SouissiOne in ten have long-term effects 8 months following mild COVID-19 – Karolinska Institutet Original study: Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers – JAMA Commentary on Twitter #LongCovid in #Frontline: JAMA Worrisome! N=323 COVID+ #Healthcare Workers vs. N=1072 w no COVID. At 8 mos, up to 4x […]
The post Cohort study: One in ten have long-term effects 8 months following mild COVID-19 appeared first on Links Medicus.
Study finds low risk of venous thromboembolism in outpatients with Covid-19 – researchers advise against the use of anticoagulants outside clinical trials
jeudi, 08 avril 2021 11:08 Écrit par Zouhair SouissiIncidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California – JAMA Internal Medicine Commentaries: VTE Related to SARS-CoV-2 Infection Less Of a Problem in Outpatients – TCTMD AND No Increase Seen in Outpatient VTE for SARS-CoV-2-Positive Patients – Physician’s Weekly Commentary on Twitter […]
The post Study finds low risk of venous thromboembolism in outpatients with Covid-19 – researchers advise against the use of anticoagulants outside clinical trials appeared first on Links Medicus.
UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca
jeudi, 08 avril 2021 11:08 Écrit par Zouhair SouissiUK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca – GOV.UK Original report: MHRA issues new advice, concluding a possible link between COVID-19 Vaccine AstraZeneca and extremely rare, unlikely to occur blood clots – Medicines and Healthcare products Regulatory Agency Commentary: Expert reaction to statements from MHRA and EMA in relation […]
The post UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca appeared first on Links Medicus.
JCVI statement on use of the AstraZeneca COVID-19 vaccine: “JCVI currently advises that it is preferable for adults aged
jeudi, 08 avril 2021 11:08 Écrit par Zouhair SouissiJCVI statement on use of the AstraZeneca COVID-19 vaccine: 7 April 2021 – GOV.UK Commentaries: Covid: Under-30s offered alternative to Oxford-AstraZeneca jab – BBC AND Expert reaction to statements from MHRA and EMA in relation to the AstraZeneca vaccine and rare blood clots and low blood platelets – Science Media Centre
The post JCVI statement on use of the AstraZeneca COVID-19 vaccine: “JCVI currently advises that it is preferable for adults aged <30 years to be offered an alternative COVID-19 vaccine, if available.” appeared first on Links Medicus.
